This article is more than 5 years old. Information may no longer be current.
Combination of micro-stent implant, cataract surgery lowers IOP in open-angle glaucoma
Click Here to Manage Email Alerts
SAN FRANCISCO — In mild to moderate open-angle glaucoma, suprachoroidal micro-stent implantation in conjunction with phacoemulsification may safely lower IOP, according to a presenter here.
The objective of the device is to sustain a low IOP, as well as reduce the dependence on antihypertensive medications, Steven D. Vold, MD, said at the American Glaucoma Society annual meeting.
The CyPass micro-stent (Transcend Medical) reduces IOP by increasing aqueous outflow toward the suprachoroidal space.
The CyPass clinical program has implanted more than 1,000 patients to date.
Citing the CyCLE study, Vold said 232 patients received combination treatment of the CyPass micro-stent with cataract surgery. Of those patients, 74 were on three or more antihypertensive medications, 145 were on one to two medications, and 13 were on no medications.
Of the 145 patients on one to two medications, 51 had an uncontrolled IOP higher than 21 mm Hg, and 94 had a controlled IOP lower than 21 mm Hg.
Device repositioning was necessary in 0.7% of patients, and a need for additional surgical intervention was necessary in 2.8% of patients.
The upcoming release of COMPASS trial data will substantiate the long-term efficacy and benefit of the combination treatment, Vold said.
Disclosure: Vold is a consultant for Transcend Medical.